2022
Temporal and spatial topography of cell proliferation in cancer
Gaglia G, Kabraji S, Rammos D, Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger O, Winer EP, Dillon DA, Zhao JJ, Sorger PK, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology 2022, 24: 316-326. PMID: 35292783, PMCID: PMC8959396, DOI: 10.1038/s41556-022-00860-9.Peer-Reviewed Original Research
2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19
Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo A, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. The Oncologist 2021, 26: 685-693. PMID: 33856099, PMCID: PMC8251362, DOI: 10.1002/onco.13794.Peer-Reviewed Original ResearchConceptsHistory of cancerIndependent risk factorDeath/hospiceSevere COVID-19Survivors of cancerHospitalized patientsCancer historyActive cancerRisk factorsCurrent cancer diagnosisCancer diagnosisCOVID-19Laboratory-confirmed COVID-19Intensive care unit admissionCare unit admissionOdds of intubationCancer-directed therapySystemic cancer therapyStandard anticancer therapiesRecent cancer treatmentUnit admissionHospice admissionMedian ageMedian timeMultivariable analysis
2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal Of Clinical Oncology 2020, 38: 4120-4129. PMID: 33052755, DOI: 10.1200/jco.20.01382.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsChemotherapy, AdjuvantHumansNeoplasmsRandomized Controlled Trials as TopicConceptsDe-escalation trialsNorth American Breast Cancer GroupBreast International GroupTreatment de-escalation trialsSystemic adjuvant therapySystemic adjuvant treatmentBreast cancer groupNoninferiority trial designAdjuvant trialsAdjuvant therapyAdjuvant treatmentCancer groupDifferent cancer typesPatient insightPatient's perspectiveEffective treatmentConsensus articleTrial designSolid tumorsField of cancerEnd pointFinancial toxicityCancer typesTrialsAdverse effects
2017
Reply to S. Sorscher
Rose BS, Winer EP, Mamon HJ. Reply to S. Sorscher. Journal Of Clinical Oncology 2017, 35: jco.2017.72.287. PMID: 28524778, DOI: 10.1200/jco.2017.72.2876.Peer-Reviewed Original Research
2016
Perils of the Pathologic Complete Response
Rose BS, Winer EP, Mamon HJ. Perils of the Pathologic Complete Response. Journal Of Clinical Oncology 2016, 34: 3959-3962. PMID: 27551115, DOI: 10.1200/jco.2016.68.1718.Peer-Reviewed Original Research
2015
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery 2015, 5: 1164-1177. PMID: 26410082, PMCID: PMC4916970, DOI: 10.1158/2159-8290.cd-15-0369.Peer-Reviewed Original ResearchConceptsBrain metastasesPrimary tumorPrimary biopsiesRegional lymph node metastasisLymph node metastasisPI3K/Akt/mTORRegional lymph nodesPotential therapeutic targetPrimary tumor biopsiesPrimary tumor samplesAkt/mTORDistinct genetic alterationsWhole-exome sequencingExtracranial metastasesLymph nodesNode metastasisDismal prognosisActionable alterationsMetastasis sitesInformative alterationsIndividualized therapyTherapeutic targetMetastasisPrimary siteEGFR inhibitorsIn Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O’Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings 2015, 90: 996-1000. PMID: 26211600, PMCID: PMC5365030, DOI: 10.1016/j.mayocp.2015.06.001.Peer-Reviewed Original ResearchSU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal Of The National Cancer Institute 2015, 107: dju493. PMID: 25688104, PMCID: PMC4342675, DOI: 10.1093/jnci/dju493.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsDrug Administration ScheduleDrug EruptionsFatigueFemaleHeterocyclic Compounds, 3-RingHumansHyperglycemiaMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeutropeniaPaclitaxelSeverity of Illness IndexTreatment OutcomeConceptsDose escalationDay 1Day 2Higher adverse eventsPhase Ib studyWeeks of therapyAdvanced solid tumorsCTCAE grade 3Metastatic breast cancerPrevious phase IPreliminary antitumor activityDose expansionStable diseaseObjective responseUnacceptable toxicityAdverse eventsMedian ageWeekly dosesClinical benefitPharmacodynamic markersSystemic exposureExcessive toxicityTumor responseGrade 3Median number
2014
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
Balmaña J, Tung N, Isakoff S, Graña B, Ryan P, Saura C, Lowe E, Frewer P, Winer E, Baselga J, Garber J. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Annals Of Oncology 2014, 25: 1656-1663. PMID: 24827126, DOI: 10.1093/annonc/mdu187.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsSolid tumorsBRCA1/2 mutationsDay 1Overall objective response rateBID days 1Grade 3 neutropeniaObjective response ratePhase I trialTreatment of patientsGermline BRCA1/2 mutationsColony-stimulating factorWarrants further investigationAdvanced breastHematologic supportMeasurable diseaseOral olaparibAdverse eventsI trialTreatment cohortsLipase elevationCisplatin dosesFrequent gradePreliminary efficacyStandard treatment
2011
American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities
Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities. Journal Of Clinical Oncology 2011, 29: 3816-3824. PMID: 21810680, DOI: 10.1200/jco.2011.35.8903.Peer-Reviewed Original ResearchConceptsCancer care disparitiesCancer careCare disparitiesAffordable Care ActCancer disparitiesClinical Oncology Policy StatementSpecific vulnerable population groupsPatient ProtectionBurden of cancerCare ActAmerican SocietyQuality of careHealth care disparitiesHealth care workforceQuality health careVulnerable population groupsVulnerable patientsClinical OncologyCareCare workforceHealth carePatientsPopulation groupsCancerHealth care lawGPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays
Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Research 2011, 39: 4928-4941. PMID: 21398628, PMCID: PMC3130254, DOI: 10.1093/nar/gkr014.Peer-Reviewed Original Research
2010
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.Peer-Reviewed Original ResearchConceptsCardiac adverse effectsCardiac toxicityCardiovascular toxicityNew drug developmentLeft ventricular ejection fraction declineVentricular ejection fraction declineAdverse effectsClassic chemotherapy agentsEjection fraction declinePotential cardiovascular toxicityRare serious complicationsNovel biologic agentsSignificant cardiac dysfunctionAcute coronary syndromeCongestive heart failureLong-term complicationsTypes of malignanciesSystemic cancer therapyLife-threatening eventsCancer therapyTyrosine kinase inhibitorsDrug developmentCardiovascular safetyCoronary syndromeBiologic agents
2009
Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2009, 27: 6052-6069. PMID: 19901123, DOI: 10.1200/jco.2009.26.6171.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchEvidence-Based MedicineFemaleFinancing, GovernmentHealth PolicyHumansMaleMass ScreeningMedical OncologyNeoplasmsPractice Guidelines as TopicPredictive Value of TestsQuality of Health CareQuality of LifeResearch Support as TopicSocieties, MedicalTime FactorsTreatment OutcomeUnited StatesConceptsClinical cancer researchClinical OncologyAmerican SocietyCancer treatmentScreening—A ReportPatients 40 yearsThird of patientsCancer researchCourse of diseaseCancer mortality ratesHealth care accessClinical research programNational Cancer InstituteHigh-quality careClinical research projectsSite of originClinical research enterpriseHigh-quality treatmentPatients' qualityPersonalized cancer medicineASCO'S PRESIDENTCare accessCancer InstituteMortality ratePatient care
2007
Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2007, 26: 313-325. PMID: 18086794, DOI: 10.1200/jco.2007.15.4088.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical Trials Cooperative GroupsClinical OncologyCancer researchAmerican SocietyCancer treatmentScreening—A ReportHormone replacement therapyBreast cancer incidenceNumber of patientsBreast cancer screeningClinical cancer researchReplacement therapyCancer research fundingHuman papillomavirusCancer careCancer patientsCancer screeningLung cancerNeck cancerCancer incidenceClinical trialsKidney cancerLiver cancerRadiation therapyDo cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations
Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM. Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. Journal Of Cancer Education 2007, 22: 21. PMID: 17570804, DOI: 10.1007/bf03174370.Peer-Reviewed Original Research
2006
Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future
Hudis CA, Winer EP. Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future. Clinical Cancer Research 2006, 12: 3576s-3580s. PMID: 16740788, DOI: 10.1158/1078-0432.ccr-06-9016.Peer-Reviewed Original Research
2005
Cancer‐related communication between female patients and male partners scale: a pilot study
Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E. Cancer‐related communication between female patients and male partners scale: a pilot study. Psycho-Oncology 2005, 15: 780-794. PMID: 16308887, DOI: 10.1002/pon.1004.Peer-Reviewed Original ResearchConceptsFemale patientsMale partnersTreatment-specific issuesFemale cancer patientsInternal consistencyCancer-related communicationCancer patientsHospital AnxietyDepression ScalePatientsProtective bufferingPilot studyItem scaleSociety websitesStudy objectiveY-MeDyadic Adjustment ScaleCancerCouples ScaleEmotional supportAdjustment ScaleHADSScale reliabilityLack of clarityUnderstanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret
Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret. Patient Education And Counseling 2005, 63: 104-109. PMID: 16242898, DOI: 10.1016/j.pec.2005.09.006.Peer-Reviewed Original ResearchAdultAnalysis of VarianceClinical Trials as TopicComprehensionDecision MakingFemaleHealth Knowledge, Attitudes, PracticeHealth Services Needs and DemandHumansInformed ConsentMaleMiddle AgedNeoplasmsPatient Education as TopicPatient ParticipationPatient SatisfactionPatient SelectionResearch SubjectsSurveys and QuestionnairesTeaching MaterialsTime FactorsUnited StatesPatient Utilities for Advanced Cancer
Wittenberg E, Winer EP, Weeks JC. Patient Utilities for Advanced Cancer. Medical Care 2005, 43: 173-181. PMID: 15655431, DOI: 10.1097/00005650-200502000-00011.Peer-Reviewed Original Research
2003
Do Patients Participating in Clinical Trials Want to Know Study Results?
Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do Patients Participating in Clinical Trials Want to Know Study Results? Journal Of The National Cancer Institute 2003, 95: 491-492. PMID: 12644548, DOI: 10.1093/jnci/95.6.491.Peer-Reviewed Original Research